Literature DB >> 18549279

Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells.

Guozhu Chen1, Ailing Li, Ming Zhao, Ying Gao, Tao Zhou, Yuanji Xu, Zhiyan Du, Xuemin Zhang, Xiaodan Yu.   

Abstract

Depsipeptide FR901228 (FK228) is a new kind of histone deacetylase inhibitors (HDACi) that induces growth arrest and cell death in a variety of tumor cells. Though its effects on oncogene expression and degradation have been documented, the detailed mechanism of FK228-induced cytotoxicity is still undefined. In this study, a differential proteomic analysis was performed to identify proteins associated with FK228-induced cytotoxicity in human lung cancer cells. Two-dimensional gel electrophoresis (2-DE) revealed a distinct protein profile of H322 cells in response to FK228 treatment, and 45 protein spots with significant alteration were screened. In total, 27 proteins were identified by mass spectrometry and involved in signal transduction, transcriptional regulation, metabolism, cytoskeletal organization, and protein folding, synthesis and degradation, consistent with multiple effects of FK228 on tumor cells. Notably, a novel target protein, thioredoxin reductase (TrxR), was identified, which is downregulated in FK228-sensitive cancer cells, but upregulated in resistant cells. The expression level of TrxR was negatively correlated with ROS accumulation, DNA damage and apoptosis, implicating TrxR in FK228-induced apoptosis and HDACi sensitivity in cancer cells. Thus, proteomic analysis provides new information about target proteins important for FK228-induced cytotoxicity in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18549279     DOI: 10.1021/pr7008753

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  10 in total

Review 1.  Discovery and mechanism of natural products as modulators of histone acetylation.

Authors:  Lilibeth A Salvador; Hendrik Luesch
Journal:  Curr Drug Targets       Date:  2012-07       Impact factor: 3.465

Review 2.  Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting.

Authors:  Georgina S Butler; Christopher M Overall
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

Review 3.  Histone deacetylase inhibitors: emerging mechanisms of resistance.

Authors:  Robert W Robey; Arup R Chakraborty; Agnes Basseville; Victoria Luchenko; Julian Bahr; Zhirong Zhan; Susan E Bates
Journal:  Mol Pharm       Date:  2011-10-07       Impact factor: 4.939

4.  Phase I trial of a new schedule of romidepsin in patients with advanced cancers.

Authors:  Laleh Amiri-Kordestani; Victoria Luchenko; Cody J Peer; Kambiz Ghafourian; James Reynolds; Deb Draper; Robin Frye; Sue Woo; David Venzon; John Wright; Monica Skarulis; William D Figg; Tito Fojo; Susan E Bates; Richard L Piekarz
Journal:  Clin Cancer Res       Date:  2013-06-11       Impact factor: 12.531

Review 5.  Histone deacetylase inhibitors: current status and overview of recent clinical trials.

Authors:  Xujun Ma; Hany H Ezzeldin; Robert B Diasio
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

6.  Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells.

Authors:  Praveen Rajendran; Emily Ho; David E Williams; Roderick H Dashwood
Journal:  Clin Epigenetics       Date:  2011-10-26       Impact factor: 6.551

7.  Crosstalk among the proteome, lysine phosphorylation, and acetylation in romidepsin-treated colon cancer cells.

Authors:  Tian-Yun Wang; Yu-Rong Chai; Yan-Long Jia; Jian-Hui Gao; Xiao-Jun Peng; Hua-Feng Han
Journal:  Oncotarget       Date:  2016-08-16

8.  dbDEPC: a database of differentially expressed proteins in human cancers.

Authors:  Hong Li; Ying He; Guohui Ding; Chuan Wang; Lu Xie; Yixue Li
Journal:  Nucleic Acids Res       Date:  2009-11-09       Impact factor: 16.971

9.  Treating Colon Cancer Cells with FK228 Reveals a Link between Histone Lysine Acetylation and Extensive Changes in the Cellular Proteome.

Authors:  Tian-yun Wang; Yan-long Jia; Xi Zhang; Qiu-li Sun; Yi-chun Li; Jun-he Zhang; Chun-peng Zhao; Xiao-yin Wang; Li Wang
Journal:  Sci Rep       Date:  2015-12-17       Impact factor: 4.379

10.  RuvBL2 is involved in histone deacetylase inhibitor PCI-24781-induced cell death in SK-N-DZ neuroblastoma cells.

Authors:  Qinglei Zhan; Sauna Tsai; Yonghai Lu; Chunmei Wang; Yiuwa Kwan; Saiming Ngai
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.